The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

RNA vaccine technology has emerged as a groundbreaking approach in the field of immunology and infectious disease prevention.

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...